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Introduction {#jah31220-sec-0004}
============

In 2011, experts estimated that ≈68 000 lives could be saved per year in the United States with optimal implementation of evidence‐based therapies in patients with heart failure with left ventricular reduced ejection fraction (HFrEF).[1](#jah31220-bib-0001){ref-type="ref"} Of 6 therapies, implementation of mineralocorticoid receptor antagonist therapy (MRA) was estimated to result in nearly a third of this potential benefit of improved care. Furthermore, 3 randomized trials have found MRAs to be a highly efficacious therapy with a low number needed to treat to save 1 life (number needed to treat to save 1 life for 1 year ≈18).[2](#jah31220-bib-0002){ref-type="ref"}, [3](#jah31220-bib-0003){ref-type="ref"} Unfortunately, only one third of eligible HF patients actually receive an MRA prescription at hospital discharge[4](#jah31220-bib-0004){ref-type="ref"} or in the outpatient setting,[5](#jah31220-bib-0005){ref-type="ref"} perhaps because MRAs have the capacity to induce potentially life‐threatening consequences by causing hyperkalemia. Furthermore, risk factors for hyperkalemia (eg, chronic kidney disease, elevated serum potassium level, potassium supplementation) are common in patients with HF, thus creating a need to balance use in ideal candidates with avoidance of use in those who are at risk for adverse consequences of therapy. Alongside the evidence of underuse, other studies have documented high rates of use (up to 1 in 6 patients) in non‐ideal patients who are at high risk[6](#jah31220-bib-0006){ref-type="ref"} for hyperkalemia.

Despite knowledge of underuse of MRA therapy, temporal trends in MRA use and variation of MRA prescribing between institutions are not well described. The assessment of temporal trends is important to understand the effectiveness of past and current efforts in narrowing the treatment gap for evidence‐based MRA use[2](#jah31220-bib-0002){ref-type="ref"}, [3](#jah31220-bib-0003){ref-type="ref"}, [7](#jah31220-bib-0007){ref-type="ref"} and therefore inform future resource allocation. Understanding institutional‐level variation is important for the design of quality improvement interventions and identification of best practices. For example, homogeneous underuse would signify that a physician‐level educational campaign is required to improve optimal MRA use, while heterogeneity in MRA prescription will indicate the need to evaluate local barriers and facilitators and possibly modeling best practices to narrow the MRA treatment gap. The aim of this study was to characterize temporal trends and hospital variation in MRA prescription for ideal and non‐ideal candidates in a nationwide cohort of veterans with HFrEF after HF hospitalization.

Methods {#jah31220-sec-0005}
=======

Human Subjects Protection {#jah31220-sec-0006}
-------------------------

This study was approved by the Providence VA Medical Center Institutional Review Board with a waiver of informed consent. Centers for Medicare and Medicaid Services data were provided with permission from Veterans Health Administration Medicare and Medicaid Analysis Center.

Data Sources {#jah31220-sec-0007}
------------

The VA External Peer Review Program is a nationwide inpatient and outpatient random sample of veterans with at least 2 years of continuous enrollment who are evaluated for evidence‐based performance measures.[8](#jah31220-bib-0008){ref-type="ref"}, [9](#jah31220-bib-0009){ref-type="ref"} VA External Peer Review Program data were linked with other VA data sets (Patient Treatment File, VA‐Medicare and Decision Support System) to obtain demographic, clinical, laboratory, healthcare utilization (VA and Medicare), and prescription data.

Study Cohort {#jah31220-sec-0008}
------------

We used the VA External Peer Review Program data from fiscal year (FY) 2003--2009 (calendar year 10/2002 to 6/2009) to identify a cohort of veterans with HFrEF, defined as left ventricular ejection fraction (LVEF) \<40% (n=37 126) (Figure [1](#jah31220-fig-0001){ref-type="fig"}). The samples from FY2003 and FY2004 were smaller than those of later years due the structure of the VA performance measurement audit system; however, the sampling strategy was unchanged. Our choice of LVEF \<40% was due to the availability of VA External Peer Review Program HF performance measure data (ie, internal quality improvement data), which identified a sample of patients with LV systolic dysfunction, as defined by LVEF \<40%. Precise quantitative information on LVEF is not available in the Veterans Health Care System to date. We restricted the study sample to veterans who were hospitalized with a principal discharge diagnosis of HF (International Classification of Diseases, Ninth Revision, Clinical Modification codes 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.93, or 428.x) within the study period and excluded patients who died before hospital discharge. We also excluded patients with no prior history of HF (because MRAs are not first‐line therapy in new diagnosis of HFrEF), length of stay \<1 day duration or \>365 days, transferred to another facility, left against medical advice, or missing serum potassium or creatinine values during index hospitalization. We also excluded patients not discharged with at least 1 of the following medications---angiotensin‐converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB), or β‐blockers---as these are recommended first‐line agents before prescription of an MRA, resulting in a study cohort of 13 411.

![Proportion of MRA use in ideal candidates=patients with MRA prescription fill (within 90 days)/patients in "Ideal Cohort." Proportion of MRA use in non‐ideal candidates=patients with MRA prescription fill (within 90 days)/patients in "Non‐Ideal Cohort." ACE indicates angiotensin‐converting enzyme; ARB, angiotensin‐receptor blocker; BB, β‐blocker; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist.](JAH3-4-e002268-g001){#jah31220-fig-0001}

Ideal and Non‐Ideal Cohorts {#jah31220-sec-0009}
---------------------------

American College of Cardiology/American Heart Association guidelines recommend careful patient selection for MRA therapy, specifically noting that HFrEF patients should only be considered if they have serum creatinine ≤2.5 (men) or estimated glomerular filtration rate \>30 mL/min per 1.73 m^2^, and serum potassium \<5.0 mEq/L. Of the study cohort of 13 411, 4096 patients had a contraindication to MRA therapy or were guideline ineligible; this was the "Non‐Ideal Cohort." These factors included a history of hyperkalemia (ICD‐9 276.7 or serum potassium ≥6.0), pre‐discharge (within 2 days) serum potassium ≥5.0 or serum creatinine \>2.5 in men and \>2.0 in women, gynecomastia (ICD9 611.1) or mastodynia (ICD9 611.71), dialysis treatment (585.6 or V45.11), or concomitant prescription of both ACE inhibitor and ARB within 90 days of discharge. The remaining 9355 patients constituted the "Ideal Cohort" who met all criteria for MRA therapy.

Outcomes Measures and Definitions {#jah31220-sec-0010}
---------------------------------

The primary outcome measure was prescription (≥14 pills) of an MRA within 90 days of hospital discharge in Ideal and Non‐Ideal candidates. Because VA hospitals typically fill new patient prescriptions prior to hospital discharge, we included any inpatient prescriptions (≥14 pills) within 48 hours preceding discharge. A 14‐pill count was chosen because it represented a minimum 2‐week supply. All discharge medications were determined in the same manner. The 90‐day period was chosen because this period reflects the treatment strategy after HF hospitalization. Furthermore, a prior study found that some MRA‐eligible patients who were not prescribed an MRA at discharge subsequently filled a prescription within 90 days.[10](#jah31220-bib-0010){ref-type="ref"}

Covariates {#jah31220-sec-0011}
----------

The following covariates were included as potential correlates of prescription of MRA: demographic characteristics (age, sex, race), vital signs (pulse, systolic blood pressure), medical history (all 29 comorbidities as defined by Elixhauser et al,[11](#jah31220-bib-0011){ref-type="ref"} pacemaker \[v45.01\], defibrillator \[v45.02\], noncompliance \[ICD‐9 v15.81\]), results of laboratory testing at discharge (hemoglobin, potassium, sodium, creatinine, blood urea nitrogen, and digoxin level), and medication prescription within 90 days of discharge (potassium supplement, loop‐ and thiazide‐type diuretics, β‐blocker, ACE inhibitor or ARB, lipid‐lowering agent, warfarin, and digoxin).

Statistical Analysis {#jah31220-sec-0012}
--------------------

### Patient‐level analyses {#jah31220-sec-0013}

We calculated the proportions of patients who received an MRA prescription within 90 days of discharge in the Ideal and Contraindication cohorts. We then applied the Cochran‐Armitage trend test to assess temporal trends across the study period (FY2003--2009). Next, we assessed the correlates of MRA use in the Ideal cohort by comparing patient demographics, vital signs, medications, lab values, and existing comorbidities among veterans who received a MRA prescription within 90 days of discharge compared to those who did not, using χ^2^ tests for categorical covariates and 1‐way ANOVAs for continuous variables. We included noncompliance (ICD‐9 v15.81) with medical treatment as a covariate for exploratory purposes. This was not intended to be a surrogate for patients who would not be expected to comply with MRA prescription, since a provider\'s assessment of patient\'s capacity for medication adherence cannot be assessed by administrative code alone. We utilized logistic regression with MRA prescription at discharge as the dependent variable and a backward selection procedure was used for covariate selection with a criterion of *P*\<0.10 for model entry and termination. To determine the effects of practice variation in MRA prescription (in Ideal and Non‐Ideal cohorts), we used generalized estimating equations to calculate the median odds ratio[12](#jah31220-bib-0012){ref-type="ref"} (MOR). Models were adjusted for patient‐level clinical and demographic characteristics as well as fiscal year to account for time trends and VA facility to account for clustering by the institution. A MOR of 1.0 suggests no meaningful variation in the odds of 2 individuals with similar characteristics receiving a MRA prescription at different, randomly selected hospitals, whereas an increase of MOR \>1.0 (eg, MOR of 2.0) indicates that the odds of receiving a MRA prescription would be 2‐fold higher for 2 patients with identical characteristics discharged from randomly selected hospitals. Based on previous literature, a MOR \>1.2 indicates significant practice‐level variation.[13](#jah31220-bib-0013){ref-type="ref"}

### Hospital‐level analyses {#jah31220-sec-0014}

To describe institutional‐level variation in MRA prescription among Ideal and Non‐Ideal patients, we assessed the distributions and interquartile ranges of MRA prescription by institution. In this analysis, we excluded hospitals with \<2 eligible patients per fiscal year. We then conducted a sensitivity analysis in which we excluded hospitals with \<20 candidates for MRA therapy from FY2003 to 2009 to determine whether volume of eligible patients may contribute to institutional‐level variation in MRA prescription practices. We then used Spearman correlation to estimate the correlation in hospital‐level MRA prescription between Ideal and Non‐Ideal candidates.

All analyses were performed using the SAS statistical package version 9.3 (Cary, NC) and approved by the Providence VAMC Institutional Review Board. Tests were 2‐tailed and *P*\<0.05 was considered statistically significant.

Results {#jah31220-sec-0015}
=======

Baseline Characteristics {#jah31220-sec-0016}
------------------------

The characteristics of the overall, Ideal, and Non‐Ideal cohorts are presented in Table [1](#jah31220-tbl-0001){ref-type="table-wrap"}. For the overall cohort, only 2% had filled a MRA prescription prior to hospitalization, but \>90% of patients filled prescriptions for a β‐blocker or ACE inhibitor (or ARB) at discharge. Mean serum potassium at discharge was 4.1 mEq/L (SD=0.5), and serum creatinine was 1.6 mg/dL (SD=1.2). Patients had a mean of 4.8 (SD=2.6) comorbidities (defined by Elixhauser[11](#jah31220-bib-0011){ref-type="ref"}) in the prior 2 years. One in 6 patients had a history of noncompliance (ICD‐9 v15.81) with medical treatment.

###### 

Baseline Characteristics of Cohort

                                                                                        Overall        Ideal MRA Candidates   Non‐Ideal MRA Candidates
  ------------------------------------------------------------------------------------- -------------- ---------------------- --------------------------
  Demographics                                                                                                                
  Year                                                                                                                        
  2003, n (%)                                                                           185 (1)        111 (1)                74 (2)
  2004, n (%)                                                                           130 (1)        92 (1)                 38 (1)
  2005, n (%)                                                                           2334 (17)      1552 (17)              782 (19)
  2006, n (%)                                                                           3488 (26)      2434 (26)              1054 (26)
  2007, n (%)                                                                           3923 (29)      2696 (29)              1227 (30)
  2008, n (%)                                                                           1307 (10)      985 (11)               322 (8)
  2009, n (%)                                                                           2044 (15)      1485 (16)              559 (14)
  Age at index date, mean (SD)                                                          71 (11)        71 (11)                71 (11)
  Female, n (%)                                                                         131 (1)        88 (1)                 43 (1)
  Race                                                                                                                        
  White                                                                                 8783 (69%)     6154 (70%)             2629 (68%)
  African American                                                                      3373 (27%)     2313 (26%)             1060 (27%)
  Other                                                                                 504 (4%)       323 (4%)               181 (5%)
  Medications prior to index admission (\<90 days)                                                                            
  MRA (spironolactone, eplerenone)                                                      306 (2%)       178 (2%)               128 (3%)
  Medications at discharge/within 90 days                                                                                     
  Loop diuretics, %                                                                     12 739 (95%)   9010 (96%)             3729 (92%)
  Thiazide diuretics, %                                                                 2325 (17%)     1453 (16%)             872 (22%)
  β‐Blocker (all), %                                                                    12 386 (92%)   8740 (93%)             3646 (90%)
  ACEI or ARB, %                                                                        12 025 (90%)   8811 (94%)             3214 (79%)
  Warfarin                                                                              4380 (33%)     3135 (34%)             1245 (31%)
  Digoxin                                                                               5611 (42%)     3984 (43%)             1626 (40%)
  Admission vitals                                                                                                            
  Systolic BP, mm Hg, mean (SD)                                                         130 (26)       130 (25)               129 (27)
  Pulse, beats/min, mean (SD)                                                           83 (19)        84 (19)                82 (19)
  BMI (kg/m^2^), mean (SD)                                                              29 (7)         29 (7)                 29 (7)
  Discharge lab values                                                                                                        
  Sodium, mEq/L, mean (SD)                                                              138 (5)        138 (4)                137 (6.58)
  Potassium, mEq/L, mean (SD)                                                           4.1 (0.5)      4.1 (0.4)              4.3 (0.6)
  Serum creatinine, mg/dL, mean (SD)                                                    1.6 (1.2)      1.4 (0.4)              2.3 (1.9)
  Blood urea nitrogen, mg/dL, mean (SD)                                                 32 (20)        28 (14)                44 (27)
  Hemoglobin, g/dL, mean (SD)                                                           12.3 (1.9)     12.6 (1.9)             11.7 (1.9)
  Comorbid conditions                                                                                                         
  Total comorbidities (Elixhauser[11](#jah31220-bib-0011){ref-type="ref"}), mean (SD)   4.8 (2.6)      4.3 (2.4)              6.0 (2.6)
  Peripheral vascular disease                                                           2531 (19%)     1554 (17%)             977 (24%)
  Hypertension, n (%)                                                                   11 510 (86)    7878 (84)              3632 (90)
  Chronic pulmonary disease                                                             6216 (46%)     4176 (45%)             2040 (50%)
  Diabetes (uncomplicated)                                                              6792 (51%)     4452 (48%)             2340 (58%)
  Diabetes (complicated)                                                                2544 (19%)     1328 (14%)             1216 (30%)
  Hypothyroidism                                                                        1576 (12%)     1032 (11%)             544 (13%)
  Liver disease                                                                         858 (6%)       489 (5%)               369 (9%)
  Metastatic cancer                                                                     147 (1%)       98 (1%)                49 (1%)
  Fluid and electrolyte disorders                                                       5043 (38%)     2621 (28%)             136 (3%)
  Deficiency anemias                                                                    4775 (36%)     2782 (30%)             1993 (49%)
  Drug abuse                                                                            940 (7%)       644 (7%)               296 (7%)
  Depression                                                                            1853 (14%)     1230 (13%)             623 (15%)
  Additional comorbid conditions                                                                                              
  Cardiac arrhythmias (from Quan[14](#jah31220-bib-0014){ref-type="ref"})               8551 (64%)     5877 (63%)             2674 (66%)
  Ischemic heart disease                                                                10 501 (78%)   7153 (76%)             3348 (83%)
  Pulmonary circulation disorders                                                       1979 (15%)     1267 (14%)             712 (18%)
  Valvular disease                                                                      3828 (29%)     2564 (27%)             1264 (31%)
  Noncompliance[a](#jah31220-note-0002){ref-type="fn"}                                  2314 (17%)     1562 (17%)             752 (19%)

ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin‐receptor blocker; BMI, body mass index; BP, blood pressure; MRA, mineralocorticoid receptor antagonist.

History of past noncompliance (ICD‐9, International Statistical Classification of Diseases, 9th Revision, v15.81).

Proportion and Trends in MRA Use in Ideal Candidates {#jah31220-sec-0017}
----------------------------------------------------

Thirty‐six percent (n=3408) of Ideal candidates (n=9355) were prescribed a MRA within 90 days of discharge (Table [2](#jah31220-tbl-0002){ref-type="table-wrap"}), of whom virtually all (99%) prescriptions were spironolactone. From 2003 to 2009, there was a significant decrease in the proportion of MRA prescriptions within 90 days of discharge from 41% (46/111) in 2003 to 31% in 2009 (465/1485) (*P*\<0.001 for trend) (Figure [2](#jah31220-fig-0002){ref-type="fig"}). This trend persisted when restricting analysis to patients (n=8196) who received both a β‐blocker and ACE inhibitor (or ARB) within 90 days of discharge (from 45% to 31%, *P*\<0.0001).

###### 

Correlates of MRA Prescription in Ideal Candidates Within 90 Days of Hospital Discharge

                                                                                        Received MRA (n=3408)   Did Not Receive MRA (n=5947)   Unadjusted *P* Value
  ------------------------------------------------------------------------------------- ----------------------- ------------------------------ --------------------------
  Demographics                                                                                                                                 
  Year                                                                                                                                         Overall trend *P*\<0.001
  2003, (%)                                                                             41%                     59%                            
  2004, (%)                                                                             39%                     61%                            
  2005, (%)                                                                             41%                     60%                            
  2006, (%)                                                                             36%                     64%                            
  2007, (%)                                                                             38%                     62%                            
  2008, (%)                                                                             34%                     67%                            
  2009, (%)                                                                             31%                     69%                            
  Age at index date, mean (SD)                                                          67 (12)                 71 (12)                        \<0.001
  Female, (%)                                                                           1.1%                    0.9%                           0.38
  Race                                                                                                                                         \<0.001
  White                                                                                 68%                     71%                            
  African American                                                                      29%                     25%                            
  Other                                                                                 4%                      4%                             
  Medications at discharge/within 90 days                                                                                                      
  Loop diuretics, %                                                                     97%                     96%                            \<0.001
  Thiazide diuretics, %                                                                 19%                     14%                            \<0.001
  β‐Blocker (all), %                                                                    95%                     93%                            \<0.001
  ACEI or ARB, %                                                                        95%                     94%                            \<0.001
  Warfarin                                                                              36%                     32%                            \<0.001
  Digoxin                                                                               52%                     37%                            \<0.001
  Admission vitals                                                                                                                             
  Systolic BP, mm Hg                                                                    128 (25)                132 (25)                       \<0.001
  Pulse, beats/min                                                                      84 (20)                 83 (19)                        0.009
  BMI (kg/m^2^)                                                                         30 (7)                  29 (7)                         \<0.001
  Discharge lab values                                                                                                                         
  Sodium, mEq/L, mean (SD)                                                              137 (4)                 138 (4)                        \<0.001
  Potassium, mEq/L, mean (SD)                                                           4.1 (0.4)               4.0 (0.4)                      0.23
  Serum creatinine, mg/dL, mean (SD)                                                    1.3 (0.4)               1.4 (0.4)                      \<0.001
  Blood urea nitrogen, mg/dL, mean (SD)                                                 27 (14)                 28 (14)                        0.001
  Hemoglobin, g/dL, mean (SD)                                                           12.7 (1.8)              12.5 (1.9)                     \<0.001
  Comorbid conditions                                                                                                                          
  Total comorbidities (Elixhauser[11](#jah31220-bib-0011){ref-type="ref"}), mean (SD)   4.4 (2.4)               4.3 (2.3)                      0.31
  Peripheral vascular disease                                                           15%                     17%                            0.02
  Hypertension, n (%)                                                                   85%                     84%                            0.41
  Chronic pulmonary disease                                                             44%                     45%                            0.27
  Diabetes (uncomplicated)                                                              51%                     46%                            \<0.001
  Diabetes (complicated)                                                                15%                     14%                            0.047
  Hypothyroidism                                                                        11%                     11%                            0.63
  Liver disease                                                                         7%                      4%                             \<0.001
  Fluid and electrolyte disorders                                                       30%                     27%                            0.005
  Deficiency anemias                                                                    29%                     30%                            0.47
  Depression                                                                            15%                     12%                            \<0.001
  Additional comorbid conditions                                                                                                               
  Cardiac arrhythmias (from Quan[14](#jah31220-bib-0014){ref-type="ref"})               63%                     63%                            0.42
  Ischemic heart disease                                                                76%                     77%                            0.97
  Pulmonary circulation disorders                                                       15%                     13%                            0.02
  Valvular disease                                                                      27%                     28%                            0.41
  Noncompliance[a](#jah31220-note-0004){ref-type="fn"}                                  18%                     16%                            0.03

ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin‐receptor blocker; BMI, body mass index; BP, blood pressure; ICD, implantable cardioverter defibrillator; MRA, mineralocorticoid receptor antagonist.

History of past noncompliance (ICD‐9, International Statistical Classification of Diseases, 9th Revision, v15.81).

![Between FY2003 to 2009, there was a significant decrease in proportion of MRA prescriptions within 90 days from 41% (46/111) to 31% (465/1485) (*P*\<0.001 for trend). This trend persisted when restricting analysis to patients (n=8196) who received both a β‐blocker and ACE inhibitor (or ARB) within 90 days of discharge (from 45% to 31%, *P*\<0.0001). ACE indicates angiotensin‐converting enzyme; ARB, angiotensin‐receptor blocker; MRA, mineralocorticoid receptor antagonist.](JAH3-4-e002268-g002){#jah31220-fig-0002}

Proportion and Trends in MRA Use in Non‐Ideal Candidates {#jah31220-sec-0018}
--------------------------------------------------------

Twenty‐seven percent (n=1096) of Non‐Ideal patients (n=4056) received a MRA prescription. From 2003 to 2009, there was a significant decrease in MRA prescriptions from 34% (25/74) to 22% (123/559) (*P*\<0.001 for trend), respectively (Figure [3](#jah31220-fig-0003){ref-type="fig"}). This temporal trend was consistent for all 3 subcategories of contraindicated MRA prescription: documented MRA contraindication (*P*=0.0013), serum creatinine \>2.5 mg/dL in men or \>2.0 mg/dL in women (*P*=0.0004), and serum potassium \>5.0 mEq/L (*P*=0.03).

![From FY2003 to 2009, there was a significant decrease in mineralocorticoid receptor antagonist (MRA) prescriptions from 34% (25/81) to 22% (158/720) (*P*\<0.001 for trend), respectively. The number (n) of Non‐Ideal candidates is indicated below each fiscal year. This temporal trend was consistent for all 3 subcategories of contraindicated MRA prescription: documented MRA contraindication (*P*=0.0013), serum creatinine \>2.5 mg/dL (or \>2.0 mg/dL in women) (*P*=0.0004), and serum potassium \>5.0 mEq/L (*P*=0.03). ACE indicates angiotensin‐converting enzyme; ARB, angiotensin‐receptor blocker.](JAH3-4-e002268-g003){#jah31220-fig-0003}

Hospital‐Level Variation {#jah31220-sec-0019}
------------------------

Among hospitals with at least 2 eligible candidates per fiscal year, the hospital‐level MRA prescribing rate (n=125 hospitals) for Ideal candidates ranged from 0% to 71% (median 36% \[interquartile range 28, 45\]) (Figure [4](#jah31220-fig-0004){ref-type="fig"}A). The corresponding rate for Non‐Ideal candidates (n=120 hospitals) ranged from 0% to 100% (median 26% \[interquartile range 18, 34\]) (Figure [4](#jah31220-fig-0004){ref-type="fig"}B). Sensitivity analysis restricting to hospitals with at least 20 Ideal and Non‐Ideal candidates for MRA therapy, respectively, during the study period demonstrated very similar results (Figure [5](#jah31220-fig-0005){ref-type="fig"}A and [5](#jah31220-fig-0005){ref-type="fig"}B). The hospital‐level MRA prescribing rate for Ideal Candidates (n=104 hospitals) ranged from 11% to 65% (median 37% \[interquartile range 29, 44\]) and for Non‐Ideal candidates (n=72 hospitals) ranged from 9% to 58% (median 24% \[interquartile range 19, 31\]). There was a positive correlation between MRA use in Ideal and Non‐Ideal candidates, with higher rates of use in Non‐Ideal candidates at institutions with higher rates of use in Ideal candidates (Figure [6](#jah31220-fig-0006){ref-type="fig"}A); the Spearman correlation coefficient was *r*=0.41 (*P*\<0.0001). Restricting to institutions with at least 20 Ideal and Non‐Ideal candidates for MRA therapy during the study period, respectively, the correlation was similar (*r*=0.39, *P*\<0.001, Figure [6](#jah31220-fig-0006){ref-type="fig"}B).

![A, Of VA hospitals with at least 2 Ideal candidates for MRA therapy (n=125 hospitals) in a given fiscal year, the hospital‐level MRA prescription rate is shown on the *Y* axis. The black bar indicates the median rate of 36% (interquartile range 28, 45). B, Of VA hospitals with at least 2 Non‐Ideal candidates for MRA therapy (n=120 hospitals) in a given fiscal year, the hospital‐level MRA prescription rate is shown on the *Y* axis. The black bar indicates the median rate of 26% (interquartile range 18, 34). MRA indicates mineralocorticoid receptor antagonist; VA, Veterans Affairs.](JAH3-4-e002268-g004){#jah31220-fig-0004}

![A, Of VA hospitals with at least 20 Ideal candidates for MRA therapy (n=104 hospitals) during the study period, the hospital‐level MRA prescription rate is shown on the *Y* axis. The black bar indicates the median rate of 37% (interquartile range 29, 44). B, Of VA hospitals with at least 20 Non‐Ideal candidates for MRA therapy (n=72 hospitals) during the study period, the hospital‐level MRA prescription rate is shown on the *Y* axis. The black bar indicates the median rate of 24% (interquartile range 19, 31). MRA indicates mineralocorticoid receptor antagonist; VA, Veterans Affairs.](JAH3-4-e002268-g005){#jah31220-fig-0005}

![A, This scatterplot demonstrates a positive correlation between mineralocorticoid receptor antagonist (MRA) prescriptions in Ideal and Non‐Ideal candidates at the hospital level. B, This scatterplot demonstrates a positive correlation between MRA prescriptions in Ideal and Non‐Ideal candidates at the hospital level. Only hospitals with ≥20 Ideal and Non‐Ideal candidates, respectively, during the study period were included.](JAH3-4-e002268-g006){#jah31220-fig-0006}

Effect of Hospital Variation on the Individual Patient: MOR of MRA Prescription in Ideal and Non‐Ideal Cohorts {#jah31220-sec-0020}
--------------------------------------------------------------------------------------------------------------

Univariate predictors of MRA prescription are listed in Table [2](#jah31220-tbl-0002){ref-type="table-wrap"}. Compared with patients who did not receive a MRA prescription, MRA‐treated patients had slightly better renal function (serum creatinine and blood urea nitrogen), but there was no difference in serum potassium between the 2 groups. Multivariable predictors of MRA prescription (*P*\<0.05) are listed in Table [3](#jah31220-tbl-0003){ref-type="table-wrap"}. Of these predictors, prescription of digoxin, lower age, lower systolic blood pressure, and presence of liver disease accounted for the greatest percentage of total variability in MRA use. Importantly, a coded diagnosis of noncompliance was not predictive of MRA prescription. After adjustment for patient predictors and clustering within hospitals, the MORs of MRA prescription for Ideal and Non‐Ideal candidates were 1.44 and 1.36, respectively, suggesting significant practice variation. In other words, for 2 individuals discharged from 2 randomly selected hospitals, the odds of 1 of them being prescribed with an MRA would be 44% higher (for Ideal candidates) and 36% higher (for Non‐Ideal candidates) than for the other individual, despite similar characteristics and indications/contraindications for therapy.

###### 

Patient‐Level Predictors of MRA Prescription in Ideal Candidates[a](#jah31220-note-0006){ref-type="fn"}

  Comparison                                                                      Odds Ratio (95% CI)    *F* Value   *P* Value
  ------------------------------------------------------------------------------- ---------------------- ----------- -----------
  Race                                                                                                   7.67        \<0.001
  Black vs white                                                                  1.28 (1.13, 1.44)                  
  Hospitalization year                                                                                   3.80        \<0.001
  2003 vs 2009                                                                    1.22 (0.79, 1.88)                  
  2004 vs 2009                                                                    1.30 (0.81, 2.09)                  
  2005 vs 2009                                                                    1.43 (1.21, 1.69)                  
  2006 vs 2009                                                                    1.12 (0.96, 1.31)                  
  2007 vs 2009                                                                    1.28 (1.10, 1.49)                  
  2008 vs 2009                                                                    1.12 (0.93, 1.36)                  
  Age (per 1 year from mean)                                                      0.98 (0.98, 0.99)      60.42       \<0.001
  Total comorbidities (per comorbidity)[11](#jah31220-bib-0011){ref-type="ref"}   0.93 (0.90, 0.96)      19.10       \<0.001
  Serum sodium, per mEq/L                                                         0.97 (0.96, 0.99)      18.28       \<0.001
  Serum creatinine, per mg/dL                                                     0.81 (0.71, 0.92)      10.93       0.001
  Body mass index, per kg/m^2^                                                    1.01 (1.01, 1.02)      11.42       \<0.001
  Systolic BP, admission (per mm Hg)                                              0.993 (0.991, 0.995)   43.84       \<0.001
  Hypertension (complicated)                                                      1.22 (1.06, 1.41)      7.57        0.006
  Diabetes (uncomplicated)                                                        1.28 (1.15, 1.42)      19.80       \<0.001
  Diabetes (complicated)                                                          1.17 (1.01, 1.36)      4.51        0.03
  Liver disease                                                                   1.86 (1.49, 2.31)      30.40       \<0.001
  Metastatic cancer                                                               0.29 (0.15, 0.54)      15.02       \<0.001
  Fluid and electrolyte disorders                                                 1.26 (1.12, 1.43)      14.09       \<0.001
  Deficiency anemias                                                              1.18 (1.05, 1.33)      7.60        0.006
  Drug abuse                                                                      0.73 (0.59, 0.91)      7.60        0.006
  Depression                                                                      1.31 (1.13, 1.52)      12.92       \<0.001
  Loop diuretic                                                                   1.69 (1.29, 2.21)      14.47       \<0.001
  Thiazide diuretic                                                               1.24 (1.09, 1.41)      10.36       0.001
  Digoxin                                                                         1.65 (1.50, 1.82)      99.36       \<0.001

BP indicates blood pressure; MRA, mineralocorticoid receptor antagonist.

Adjusted for clustering within hospital.

Discussion {#jah31220-sec-0021}
==========

In a national cohort of veterans discharged for HF between 2003 and 2009, MRA prescription decreased over time. MRA prescription fell not only in Non‐Ideal candidates, but unexpectedly fell in Ideal candidates. The MORs of MRA prescription for both Ideal and Non‐Ideal candidates indicate significant institutional‐level variation. These findings suggest that many patients who could benefit from MRAs are still not receiving them and that there is a wide gap between high‐ and low‐performing institutions.

This is to our knowledge the first study to report hospital‐level variation in MRA prescribing. The MOR for both Ideal and Non‐Ideal candidates were above the threshold required to indicate significant practice‐level variation, defined as MOR \>1.2.[13](#jah31220-bib-0013){ref-type="ref"} Indeed, the degree of variation in MRA prescription was comparable with practice‐level variation in warfarin prescribing (MOR 1.3) in patients with atrial fibrillation.[13](#jah31220-bib-0013){ref-type="ref"} However, the practice variation was lower when compared to variation of other performance measures such as primary percutaneous intervention within 90 minutes (MOR 2.2), smoking cessation instructions (MOR 2.7), and cardiac rehabilitation referral (MOR 4.8).[15](#jah31220-bib-0015){ref-type="ref"} This hospital‐level heterogeneity in MRA prescribing suggests there are significant opportunities to improve MRA utilization by assessing the local barriers and intervening on hospitals with lower MRA use in ideal candidates while learning from hospitals that have higher MRA use.

Another important finding is the declining MRA prescription in Ideal candidates during the study period. These findings in a broad national sample of hospitalized veterans who met criteria for MRA therapy confirm the findings of other registry[4](#jah31220-bib-0004){ref-type="ref"}, [10](#jah31220-bib-0010){ref-type="ref"}and single‐center[16](#jah31220-bib-0016){ref-type="ref"} studies, which found that only approximately one quarter to one third of eligible HF patients receive a MRA. From the Get With The Guidelines‐Heart Failure (GWTG‐HF) national registry (2005--2007) of hospitalized patients with HF, Albert et al reported that 32.5% of the eligible cohort received a MRA prescription at discharge.[4](#jah31220-bib-0004){ref-type="ref"} However, in that study the proportion of patients who received a MRA prescription increased from 28% to 34% over the 3‐year study period, in contrast to the declining trend of 41% to 31% found in our study from 2003 to 2009. This declining trend persisted in a sensitivity analysis that included only those patients treated with *both* β‐blockers and ACE inhibitors, an approach advocated in the European Society of Cardiology Heart Failure guideline[17](#jah31220-bib-0017){ref-type="ref"} when selecting patients for MRA therapy. The reasons for these contrasting temporal trends between the 2 studies could be due to different duration of comparison (7 versus 3 years) or a greater MRA utilization at VA hospitals after the Randomized Aldactone Evaluation Study trial,[3](#jah31220-bib-0003){ref-type="ref"} which regressed to the national baseline over time. Another possibility is that non‐VA, Get With The Guidelines hospitals benefited from participating in a quality‐improvement registry that provides hospitals with performance data on their MRA utilization rates. In contrast, while VA hospitals did establish a HF Network (community of practitioners) and collect basic HF performance data (ACE/ARB for LVEF \<40%, measurement of LVEF, smoking cessation, discharge instructions), they did not participate in the Get With The Guidelines registry and did not have specific quality‐improvement efforts targeting MRA utilization. Nonetheless, the widening MRA treatment gap in the VA over time suggests opportunities for improvement and merits additional investigation.

The proportion of Non‐Ideal candidates (27%) who were prescribed a MRA was much higher than that found in the Get With The Guidelines study of Albert et* *al[4](#jah31220-bib-0004){ref-type="ref"} (≈10%) in a 2005--2007 cohort or an earlier study in a post‐Randomized Aldactone Evaluation Study cohort[6](#jah31220-bib-0006){ref-type="ref"} (2000--2001), which found a proportion of 17%. Our observed proportion may have been higher because we utilized clinical and administrative data with a 2‐year "look‐back" regarding history of contraindications and included historical laboratory values of prior hyperkalemia (potassium ≥6.0 mEq/L); this approach was likely very sensitive to detect potential MRA prescribing in Non‐Ideal candidates. While there are differences in how studies defined inappropriate prescribing, our finding has 2 implications. First, though MRA prescribing in Non‐Ideal candidates substantially declined during the study period, it may still be a larger quality problem than has previously been acknowledged[4](#jah31220-bib-0004){ref-type="ref"} despite a 2004 publication on excess death and hyperkalemia hospitalizations associated with rising spironolactone use.[18](#jah31220-bib-0018){ref-type="ref"} Second, the positive correlation between hospital‐level use in Ideal and Non‐Ideal candidates supports concerns that efforts to increase appropriate use of MRAs could have the unintended consequence of increasing use in patients for whom therapy might be detrimental. Attempts to stimulate greater use of MRA should be accompanied by surveillance for potential overuse.

There were several methodological considerations in our study. First, we measured MRA exposure up to 90 days after hospitalization to capture a complete picture of HF pharmacotherapy in the transition from hospital to home. This is important because renal dysfunction typically worsens during and immediately after HF hospitalization[19](#jah31220-bib-0019){ref-type="ref"} and because 13% of Medicare patients with HF who are discharged without a MRA subsequently filled a new MRA prescription within 90 days.[10](#jah31220-bib-0010){ref-type="ref"} Therefore, we utilized serum potassium and creatinine values at time of hospital discharge to determine MRA eligibility rather than at admission,[4](#jah31220-bib-0004){ref-type="ref"} which mirrors the process of clinical decision making. Second, we carefully excluded patients who were not ideal for MRA therapy based on an elevated serum potassium level (≥5.0 mEq/L) prior to hospital discharge as well as those with a history of serious hyperkalemia, whether diagnosed by ICD‐9 code or evidence of an elevated potassium ≥6.0 mEq/L, as far back as 2 years. Incorporation of laboratory data is important because ICD‐9‐defined hyperkalemia underestimates the true incidence of laboratory‐defined serious hyperkalemia (serum potassium ≥6.0).[20](#jah31220-bib-0020){ref-type="ref"} Third, the study time period pre‐dated the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure trial (2011), which expanded the indication for MRAs (ie, eplerenone) in select patients with mild HF symptoms.[7](#jah31220-bib-0007){ref-type="ref"} Thus, we might not have captured the potential increase in MRA use after the publication. However, the 7‐year time window of our study provides an ample window to assess the impact on clinical practice before and after a 2004 publication on MRA‐related hyperkalemia. Fourth, our use of clinical and laboratory variables from electronic medical records in addition to standard administrative data may be more sensitive to identify patient‐specific contextual factors[21](#jah31220-bib-0021){ref-type="ref"} that would preclude use of a MRA than administrative data alone. Fifth, the VA provides a unique lens in which to examine quality of HF care. The VA is the largest integrated health system in the United States, with an electronic medical record system that allows for detailed clinical assessment of MRA indication as well as tracking of prescriptions for patients despite geographic mobility.[22](#jah31220-bib-0022){ref-type="ref"} Features common to VA hospitals such as a national formulary, electronic medical record, and academic affiliations may favor a homogeneous pattern of MRA utilization. Furthermore, veterans with HF are typically older, more symptomatic, and have more comorbidities than non‐VA patients yet have similar outcomes.[23](#jah31220-bib-0023){ref-type="ref"} Sixth, we utilized a LVEF cutoff of \<40%, rather than ≤35%, due to limitations of the VA clinical data sets, though some studies on this topic have also utilized a cutoff of LVEF \<40%.[6](#jah31220-bib-0006){ref-type="ref"}

There was a temporal decline in MRA prescription among Ideal candidates from 2003 to 2009 as well as important hospital‐level variation in MRA use for Ideal and Non‐Ideal candidates in the VA system, suggesting the importance of system factors in MRA prescribing in addition to patient factors. System efforts identifying best practices while assessing local barriers to MRA prescription will be needed to target low use of MRA in eligible patients and to reduce use in patients who could potentially be harmed.
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